Main Menu

This technology includes Borrelia hermsii isolate for diagnostic development of serologic tests. Borrelia hermsii is the major identified cause of Tick-Borne Relapsing Fever (TBRF) in humans in the western United States. Initial signs and symptoms of infection include fever, nausea, headache and malaise. Most cases are diagnosed on clinical suspicion and epidemiologic risk. Common source, case clusters notable. Microscopy and serologic detection of antibody responses to infection may aid in the laboratory confirmation or infection.

This technology includes natural Yellow Fever Virus, Zika Virus, and Powassan Virus isolates for various uses in research and development of diagnostics and immunizations.

This technology includes isolates of the Dengue Virus (type 2) which can be used to develop diagnostic tests, antivirals and vaccinations. These isolates are from Puerto Rico DENV-2 and have complete whole genome sequencing completed. Additionally, these isolates represent current stains of Dengue Virus which are circulating in the Caribbean.

This technology includes a murine IgG1 monoclonal antibody (mAb), 1C7, for the detection of Chaetomium globosum. The development of mAb-based detection methods may provide a standardized approach to quantify the target organism(s) using rapid immunoassay platforms. To date, mAbs are not available for Chaetomium species. C. globosum enolase was selected as a candidate biomarker for the detection of this species due to its presence within the cytosol and cell wall. C. globosum enolase was cloned and a recombinant expressed in Escherichia coli for the production of mAbs.

This technology includes clean, mycoplasma-free, rabies virus stocks for use in vaccine manufacturing. Rabies virus causes a nearly uniformly fatal disease, but can be prevented by timely vaccination. An inactivated rabies vaccine for human use was first prepared in cell culture in 1964, using the Pitman-Moore (PM) strain of fixed rabies virus. Typical rabies vaccine virus stocks stored at the Centers for Disease Control are heavily contaminated by mycoplasma, there this stock provides an alternative supply which is free of mycoplasma.

This technology includes a new concept to develop a bivalent IRV-IPV combination vaccine against rotavirus and polio using a dissolving microneedle patch. Specifically, we describe the formulation for IRV, the fabrication of a microneedle patch for combined IRV-IPV, and the proof of concept for assessing potential interference of immunogenicity and dose sparing in animal studies. Licensed oral rotavirus vaccines, while effective in developed and middle-income countries, are significantly less effective in reducing cases of severe diarrhea among children in developing countries.

This technology includes a novel application of chimeric monoclonal antibodies (i.e.animal-human) as substitutes for patient /organism specimens to create standardized training (TP), proficiency testing (PT), quality control (QC), lot-to-lot validation, and new serologic test evaluation and validation panels to support the implementation of quality management systems (QMS) of serology-based tests.

This technology includes a cell line of Adult T-cell Leukemia (ATL) which contains a full-length copy of the HTLV-I genome and dually expressed CD4 and CD8, which can be used for developing therapeutics against HIV and other diseases which may involve interaction with dual-positive T-cells. This cell line can also be used to study the regulation of various cellular genes by HTLV-I since it contains a single integrated copy of the virus expressing all of the viral gene products.

This technology includes Escherichia coli isolate with MCR-1 gene which can be used in the development of diagnostic tests. The MCR-1 gene makes bacteria resistant to the antibiotic colistin, which is used as a last-resort drug to treat patients with multi-drug-resistant infections, including carbapenem-resistant Enterobacteriaceae (CRE). This gene exists on a plasmid, a small piece of DNA that is capable of moving from one bacterium to another, spreading antibiotic resistance among bacterial species.

This technology includes a novel, isolated reassortant mammalian Orthoreovirus (MRV) isolated from pigs with neurological symptoms, for use in the development of vaccines and diagnostic tests. This isolate has S1 gene from MRV1 closed to bovine isolated, M2 gene from MRV2 and other 8 genes from MRV3 based on full-genome sequence analysis. MRV3 has been reported and isolated from the US pigs with diarrhea symptom. Compared to the reported swine MRV3 isolates that cause diarrhea in pigs, the novel reassortant MRV causes neurological disease in pigs.